Total Payments
$24,893
2024 Payments
$1,060
Companies
49
Transactions
1,163
Medicare Patients
5,979
Medicare Billing
$931,763
Payment Breakdown by Category
Food & Beverage$24,455 (98.2%)
Education$438.74 (1.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $24,455 | 1,137 | 98.2% |
| Education | $438.74 | 26 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $4,368 | 160 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $3,485 | 164 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,011 | 137 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,253 | 101 | $0 (2023) |
| Merck Sharp & Dohme LLC | $1,244 | 59 | $0 (2023) |
| Novo Nordisk Inc | $1,080 | 54 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,077 | 64 | $0 (2024) |
| PFIZER INC. | $1,071 | 52 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $583.59 | 55 | $0 (2021) |
| ABBVIE INC. | $505.75 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,060 | 38 | AstraZeneca Pharmaceuticals LP ($338.05) |
| 2023 | $1,700 | 59 | AstraZeneca Pharmaceuticals LP ($603.60) |
| 2022 | $1,732 | 85 | Boehringer Ingelheim Pharmaceuticals, Inc. ($442.95) |
| 2021 | $3,480 | 165 | Boehringer Ingelheim Pharmaceuticals, Inc. ($539.53) |
| 2020 | $3,479 | 149 | Janssen Pharmaceuticals, Inc ($677.16) |
| 2019 | $4,453 | 188 | Janssen Pharmaceuticals, Inc ($842.33) |
| 2018 | $4,934 | 253 | Janssen Pharmaceuticals, Inc ($1,001) |
| 2017 | $4,056 | 226 | AstraZeneca Pharmaceuticals LP ($868.16) |
All Payment Transactions
1,163 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $33.33 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $30.14 | General |
| Category: DIABETES | ||||||
| 11/15/2024 | RGH Enterprises LLC | — | Food and Beverage | In-kind items and services | $30.34 | General |
| 11/02/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: Respiratory | ||||||
| 10/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $29.93 | General |
| Category: DIABETES | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $26.92 | General |
| 10/02/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: Gastroenterology | ||||||
| 09/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $34.53 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.76 | General |
| Category: DIABETES | ||||||
| 09/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: Diabetes | ||||||
| 08/28/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: Gastroenterology | ||||||
| 08/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: DIABETES | ||||||
| 08/07/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $23.73 | General |
| Category: Diabetes | ||||||
| 07/24/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Gastroenterology | ||||||
| 07/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: DIABETES | ||||||
| 07/10/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: Diabetes | ||||||
| 06/25/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $32.95 | General |
| Category: Endocrinology | ||||||
| 06/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.64 | General |
| Category: DIABETES | ||||||
| 06/12/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Gastroenterology | ||||||
| 06/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: DIABETES | ||||||
| 06/04/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: Inflammation | ||||||
| 05/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: Diabetes | ||||||
| 05/09/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $29.23 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/07/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: Gastroenterology | ||||||
| 05/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,496 | 2,905 | $483,394 | $220,761 |
| 2022 | 16 | 1,436 | 3,280 | $496,688 | $223,725 |
| 2021 | 15 | 1,496 | 3,799 | $557,289 | $259,860 |
| 2020 | 13 | 1,551 | 3,810 | $570,135 | $227,417 |
Total Patients
5,979
Total Services
13,794
Medicare Billing
$931,763
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 239 | 717 | $111,852 | $55,768 | 49.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 353 | 559 | $120,744 | $49,378 | 40.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 258 | 258 | $86,688 | $39,456 | 45.5% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2023 | 59 | 198 | $38,016 | $18,181 | 47.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 171 | $30,780 | $18,035 | 58.6% |
| Q3014 | Telehealth originating site facility fee | Office | 2023 | 161 | 353 | $17,650 | $7,293 | 41.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 46 | $15,456 | $6,982 | 45.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 38 | $11,400 | $6,130 | 53.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 33 | 47 | $8,220 | $4,837 | 58.8% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 19 | 25 | $7,500 | $4,740 | 63.2% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 53 | 96 | $17,952 | $4,637 | 25.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $8,856 | $2,653 | 30.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 151 | 324 | $5,832 | $1,040 | 17.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 24 | 24 | $1,008 | $870.96 | 86.4% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 24 | 24 | $1,440 | $761.28 | 52.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 410 | 993 | $214,488 | $94,716 | 44.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 215 | 534 | $83,304 | $41,025 | 49.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 41 | 230 | $41,400 | $20,758 | 50.1% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2022 | 58 | 152 | $29,184 | $14,318 | 49.1% |
| Q3014 | Telehealth originating site facility fee | Office | 2022 | 288 | 676 | $33,800 | $12,682 | 37.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 43 | 66 | $22,176 | $10,998 | 49.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 43 | 66 | $11,484 | $6,133 | 53.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 35 | 39 | $11,700 | $5,922 | 50.6% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 59 | 90 | $16,830 | $4,398 | 26.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 27 | 27 | $9,072 | $4,140 | 45.6% |
About Dr. Eric Lim, MD
Dr. Eric Lim, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427130723.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Lim, MD has received a total of $24,893 in payments from pharmaceutical and medical device companies, with $1,060 received in 2024. These payments were reported across 1,163 transactions from 49 companies. The most common payment nature is "Food and Beverage" ($24,455).
As a Medicare-enrolled provider, Lim has provided services to 5,979 Medicare beneficiaries, totaling 13,794 services with total Medicare billing of $931,763. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location San Francisco, CA
- Active Since 10/19/2006
- Last Updated 10/06/2009
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1427130723
Products in Payments
- XARELTO (Drug) $2,574
- FARXIGA (Drug) $1,764
- JARDIANCE (Drug) $1,502
- TRELEGY ELLIPTA (Drug) $1,329
- ELIQUIS (Drug) $1,287
- INVOKANA (Drug) $883.15
- JANUVIA (Drug) $769.86
- BEVESPI AEROSPHERE (Drug) $709.40
- STIOLTO RESPIMAT (Drug) $611.20
- BREZTRI (Drug) $505.19
- ENTRESTO (Drug) $461.09
- Ozempic (Drug) $459.59
- SYMBICORT (Drug) $442.01
- Mitigare (Drug) $434.20
- Vascepa (Drug) $413.28
- CHANTIX (Drug) $386.77
- SPIRIVA RESPIMAT (Drug) $357.18
- Uloric (Drug) $330.86
- Victoza (Drug) $324.47
- Kerendia (Drug) $311.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Internal Medicine $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Internal Medicine $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736
Internal Medicine $732,736